Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10871778 | FEBS Letters | 2011 | 11 Pages |
Abstract
Interleukin (IL)-6 is a cytokine with multiple biological activities. It contributes to host defense against pathogens, whereas accelerated production of IL-6 plays a significant pathological role in various diseases. Clinical trials have demonstrated the efficacy of tocilizumab, a humanized anti-IL-6 receptor antibody, for patients with rheumatoid arthritis, Castleman's disease or juvenile idiopathic arthritis, leading to approval of this innovative drug for the treatment of these diseases. Since IL-6 has been demonstrated to play a significant role in the development of various other autoimmune and inflammatory diseases, tocilizumab can be expected to become a novel drug for such diseases as well.
Related Topics
Life Sciences
Agricultural and Biological Sciences
Plant Science
Authors
Toshio Tanaka, Masashi Narazaki, Tadamitsu Kishimoto,